Stockscreener 앱 받기
44.85
2.56%
-1.18
시간 외 거래:
44.83
-0.02
-0.04%
Vaxcyte Inc 주식(PCVX)의 최신 뉴스
Evercore ISI reiterates Outperform rating on Vaxcyte stock amid CDC changes - Investing.com Canada
Stock Report: Is Vaxcyte Inc stock trading near support levelsSell Signal & Daily Profit Maximizing Trade Tips - moha.gov.vn
Vaxcyte (PCVX) Gains Favor After Immunization Schedule Update - GuruFocus
Vaxcyte's Chief Technical Ops Officer Sells Shares - Yahoo Finance
Insider Sell Alert: Harpreet Dhaliwal Sells 9,743 Shares of Vaxc - GuruFocus
Harpreet Dhaliwal Sells 9,743 Shares of Vaxcyte (NASDAQ:PCVX) Stock - MarketBeat
Vaxcyte Inc. (PCVX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Price-Driven Insight from (PCVX) for Rule-Based Strategy - Stock Traders Daily
Vaxcyte, Inc. (NASDAQ:PCVX) Nasdaq Composite Tracks Clinical Progress - Kalkine Media
Trade Alert: Senior Vice President of Finance Of Vaxcyte Elvia Cowan Has Sold Stock - simplywall.st
Vaxcyte (NASDAQ:PCVX) Stock Price Up 3.9%Here's Why - MarketBeat
Vaxcyte shows rising price performance with jump to 81 RS rating - MSN
Insider Selling: Vaxcyte (NASDAQ:PCVX) SVP Sells 11,623 Shares of Stock - MarketBeat
Vaxcyte president and CFO sells shares worth $692,100 - MSN
Vaxcyte, Inc. $PCVX Shares Sold by Harbor Capital Advisors Inc. - MarketBeat
Vaxcyte Earnings Notes - Trefis
This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%. - Barron's
What Makes Vaxcyte (PCVX) So Attractive - Finviz
What makes Vaxcyte (PCVX) so attractive - MSN
How (PCVX) Movements Inform Risk Allocation Models - Stock Traders Daily
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why Vaxcyte Inc. stock remains resilientJuly 2025 Spike Watch & Weekly Watchlist of Top Performers - Улправда
Assenagon Asset Management S.A. Buys 171,974 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Will Vaxcyte Inc. stock keep outperforming rivalsM&A Rumor & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
How Vaxcyte Inc. stock performs during Fed tightening cyclesDay Trade & Safe Capital Allocation Plans - Улправда
How Vaxcyte Inc. stock performs in rate cut cyclesAnalyst Downgrade & Safe Capital Growth Trade Ideas - Улправда
Vaxcyte Enhances Executive Severance to Align With Market - TipRanks
PCVX (Vaxcyte) EV-to-OCF : -7.70 (As of Dec. 19, 2025) - GuruFocus
Profit Review: Will Vaxcyte Inc. stock attract ESG investorsWeekly Risk Summary & Reliable Intraday Trade Plans - DonanımHaber
Why Vaxcyte Inc. (5VA) stock remains stableTrade Entry Report & AI Powered Trade Plan Recommendations - Улправда
Vaxcyte enhances executive severance to align with market - MSN
Vaxcyte: Financial Durability And The Case For Disruption (NASDAQ:PCVX) - Seeking Alpha
Market Review: Why Vaxcyte Inc stock could benefit from AI revolution2025 Geopolitical Influence & Fast Moving Stock Watchlists - moha.gov.vn
Pivotal OPUS Phase 3 VAX-31 Head-to-Head Trial Could Be A Game Changer For Vaxcyte (PCVX) - simplywall.st
How Vaxcyte’s Phase 3 Head-to-Head VAX-31 Trial Could Shape Vaxcyte (PCVX) Investors - Yahoo Finance
Vaxcyte (PCVX): Assessing a Discounted Valuation After a Volatile Year in the Share Price - Yahoo Finance
Frazier Life Sciences Management L.P. Reduces Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Institutional Investors Bet Big on Vaxcyte’s Clinical Ambitions - AD HOC NEWS
Vaxcyte, Inc. $PCVX Shares Purchased by Eventide Asset Management LLC - MarketBeat
Vaxcyte, Inc. $PCVX Shares Purchased by Maverick Capital Ltd. - MarketBeat
Vaxcyte, Inc. (PCVX) makes strides on pneumonia treatment, plots coverage extension - MSN
Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension - Yahoo Finance
Trading Systems Reacting to (PCVX) Volatility - Stock Traders Daily
Vaxcyte, Inc. $PCVX Stake Increased by Diadema Partners LP - MarketBeat
Vaxcyte (PCVX) Gets a Buy from Guggenheim - The Globe and Mail
Vaxcyte (PCVX) price target increased by 19.72% to 99.96 - MSN
Vaxcyte stock maintains Buy rating at Jefferies as Phase 3 trial begins - Investing.com Canada
Vaxcyte Doses First Patients in Phase 3 Trial of VAX-31 in Invasive Pneumococcal Disease, Pneumonia - marketscreener.com
Vaxcyte announces first participants dosed in OPUS Phase 3 trial of VAX-31 - TipRanks
Vaxcyte begins phase 3 trial of pneumococcal vaccine VAX-31 - Investing.com
Vaxcyte (PCVX) Begins Phase 3 Study for Pneumonia Vaccine - GuruFocus
Vaxcyte says topline results from OPUS trial expected in Q4 2026 - marketscreener.com
Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026 - TradingView
Vaxcyte begins phase 3 trial of pneumococcal vaccine VAX-31 By Investing.com - Investing.com Canada
2.52%
0.07%
자본화:
|
볼륨(24시간):